C MR spectroscopy
RF power requirements were optimised for each subject prior to acquisition of study data to ensure consistency of 13 C tip angle and decoupler efficacy. 13 C calibration data were acquired from a fiducial marker within the coil housing that exhibited a 13 C signal with short T 1 (213 mM [2- 13 C]-acetone and 25 mM GdCl 3 in water).
13 C spectra were acquired using a pulse-acquire sequence at nominal tip angles of 25, 50, 100 and 200° (repetition time = 150 ms, spectral width = 8 kHz, 256 datapoints, 250 averages), and the discrepancy between requested and achieved tip angle calculated from the variation in signal intensity between the four spectra. This calibration procedure was designed to enable correction of differences in achieved 13 C tip angle between study volunteers resultant from differences in coil loading. However, in practice the procedure demonstrated that all three volunteers and the calibration phantom had the same 13 C RF power requirements, reflecting the similarity in coil loading between scans. 
Consistency

Relative contributions of hepatic and non-hepatic tissue to
13
C spectra A surface coil was used to localise the acquired spectra to liver tissue in our study.
Prior to human studies we performed measurements to determine the relative contribution of hepatic and non-hepatic tissue to the acquired signal. The active volume of the coil is principally liver, but also contains skin, subcutaneous fat, bone, and intercostal muscle. As the magnitude of the 13 C coil's B 1 field decreases with distance from the coil, a pulse power setting optimised for maximal hepatic signal results in an achieved tip angle greater than 90 degrees between the coil and the liver.
This results in T 1 -saturation immediately adjacent to the coil, with consequent reduction of the contribution of non-hepatic regions to the acquired spectrum. Based on our coil sensitivity measurements, on the morphology of study participants, and on the acquisition parameters used in the scan protocol, we estimate that hepatic tissue comprises 86 ± 4% by volume to the study spectra (ie. if a metabolite were distributed uniformly over hepatic and non-hepatic regions, 86% of the signal would arise from the liver (data not shown)). As non-hepatic tissue has lower glutathione content than liver, this further increases the dominance of the hepatic contribution. For these reasons we consider the contributions to the spectra from non-hepatic tissue to be sufficiently minor that they can be neglected in this study.
Acquisition of preclinical 13 C spectra to present a similar situation, aided further by the more ventral morphology of the rat liver (allowing coil positioning with minimal contribution from the ribcage and minimal separation between coil and liver). Little subcutaneous fat was observed adjacent to the coil, even in rats receiving the HFHC diet, and imaging prior to acquisition of 13 C spectra confirmed consistent positioning of the liver over the 13 C RF coil (Figure 1 F&H) . Thus for preclinical studies the contributions of non-hepatic tissue to the spectra were assumed to be negligible.
Human studies: data analysis and quantitation C]-glycine that had been prepared using the same protocol as for plasma samples.
Preclinical study methods: Preparation and analysis of tissue extracts
Frozen liver samples were homogenized at room temperature in preweighed solutions of 50 mM phosphate buffer containing 25 mM monobromobimane. Proteins were precipitated by addition of perchloric acid and removed by centrifugation, then excess perchloric acid was removed by neutralisation with potassium hydroxide. The resultant thiol-bimane conjugate extracts were freeze dried for storage, then analysed by mass spectrometry using a Thermo Surveyor liquid chromatograph coupled to a Thermo LTQ linear ion trap mass spectrometer. The fractional enrichment of glutathione-bimane with 13 C label was determined as previously described (8) .
Briefly, the isotope enrichment was calculated from the ratio of distributions of mass to charge ratio of 500, 499 and 498 amu by comparison to theoretical isotope distribution patterns calculated for glutathione-bimane using a mass spectrometry webtool (9) . Glutathione concentration in the extracts was determined using HPLC analysis of glutathione-bimane conjugates. A portion of tissue extract samples was freeze dried, resuspended in D 2 O, and 1 H MR spectra acquired using a Bruker Avance III 500 MHz spectrometer equipped with a BBO probe for n=3 samples per experimental group.
Hepatic F 2 -isoprostane were isolated from liver tissue using the methods of Davies (10) and Morrow (11), comprising chloroform/methanol extraction, hydrolysis of esterified isoprostanes in phospholipids, and purification by cation exchange solid phase extraction. F 2 -isoprostane analysis was performed using a Prominence HPLC (Shimadzu, Kyoto, Japan) equipped with a C 18 column, coupled to a Q-Trap mass spectrometer (Sciex, Warrington, UK) operated using multiple reaction monitoring in negative ion mode, monitoring the transition of the precursor F 2 isoprostane ion (with a m/z of 353) to specific productions with m/z of 193, 127 and 115 for the F 2 -III, IV and VI isomers respectively.
Preclinical study: Histology
Formalin fixed liver sections were stained with Haematoxyin and Eosin (H&E) or 0.1% Sirius Red Picric solution following standard protocols. α-smooth muscle actin antibody immunohistochemistry (α-SMA) was performed on formalin-fixed liver sections as previously described (12) . Photomicrographs were taken at x10 magnification on a Leica DMR microscope with a DFC 310 FX camera (Leica Microsystems, Wetzlar, Germany).
